Skip to content
Research Article Open access CC BY 3.0

Medical Herbalism and Herbal Clinical Research: A Global Perspective

Sunday J. Ameh, Obiageri O. Obodozie, Peace C. Babalola, Karnius S. Gamaniel

Journal of Pharmaceutical Research International · pp. 99–123 · Published 23 Jun 2011

10.9734/BJPR/2011/403

Abstract

This review aims to sensitize researchers, regulators and other stakeholders to the centrality of clinical research to drug development from herbs used in Traditional Medicine (TM). The review uncovered and dwelt on the fact that: while clinical trials of chemical medicines (pharmaceuticals) tend to come late in the drug development chain, the reverse is often the case with herbal medicines (phytomedicines). Once the decision is made to develop a single phytochemical entity (phytopharmaceutical, example: artemisinin) from a plant, the need for such sensitization is particularly desirable, given their huge socioeconomic implications. The review emphasized that drug development from a traditional herb can: i) take the route of standardization of the herb or its extract for immediate use without further chemical manipulations; or ii) proceed along the line of isolation and other manipulations aimed at optimising bioactivity. By the first route, development proceeds directly from confirming that the pharmacological property of the herb tallies with its traditional indication, leading instantly to value addition to traditional knowledge accumulated over years. This is because herbal medicines based on time tested traditions need not undergo phased trials as would a novel pharmaceutical (or an old herb for a new indication), since their long histories often offer evidence of their safety and efficacy. In the second route, clinical studies usually come later in the chain. This is because, unlike the traditional therapeutic, the new phytopharmaceutical, taken out of its natural microenvironment and subjected to various chemical manipulations, including purification, is no longer the equivalent of the ancient remedy with predicable effects. Moreover, in this later case, interest in the new entity (an artificially concentrate isolate) may shift completely from the traditional indication of the herb, hence the need for phased trials of phytopharmaceuticals (or an old herb for a new indication), despite their natural origin.

Medical herbalism Traditional Medicine drug development chain phytochemical entity pharmaceutical medicine phytopharmaceutical traditional indication clinical research

Cited by 13

Sickle cell Anaemia: The Need for Increased Drug Development in Africa

Damilola Esther Olukorede, Oluwatoyosi Rachael Farayola, Bukola Mariam Badmus · Annals of Public Health Issues · 2022

CURRENT STATUS AND CHALLENGES OF HERBAL DRUG DEVELOPMENT AND REGULATORY ASPECT: A GLOBAL PERSPECTIVE

CHOWDHURY MOBASWAR HOSSAIN, MEETA GERA, KAZI ASRAF ALI · Asian Journal of Pharmaceutical and Clinical Research · 2022

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

13

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.